Overview

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This is a phase IV, single-center, open label, single arm study in which a group of 30 subjects with moderate to severe plaque psoriasis will receive secukinumab therapy. Non-invasive imaging with optical coherence tomography (OCT) will be used to monitor the resolution of psoriatic plaques with treatment in comparison to observed clinical improvements. Early subclinical finding will be used to elucidate drug mechanism of action. Assessment will be based on intrasubject comparisons, and all findings will be compared to patients baseline imaging.

Phase:

Phase 4

Details

Lead Sponsor:

Narrows Institute for Biomedical Research

Collaborator:

Novartis

Treatments:

Antibodies, Monoclonal